{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T12:32:17Z","timestamp":1726144337831},"reference-count":41,"publisher":"Japanese Society of Toxicology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2020]]},"DOI":"10.2131\/jts.45.493","type":"journal-article","created":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T22:05:19Z","timestamp":1596405919000},"page":"493-502","source":"Crossref","is-referenced-by-count":2,"title":["Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice"],"prefix":"10.2131","volume":"45","author":[{"given":"Shingo","family":"Oda","sequence":"first","affiliation":[{"name":"Department of Drug Safety Sciences, Division of Clinical Pharmacology, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanaka","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Drug Safety Sciences, Division of Clinical Pharmacology, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Tsuneyama","sequence":"additional","affiliation":[{"name":"Department of Molecular and Environmental Pathology, Institute of Health Biosciences, Tokushima University Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Yokoi","sequence":"additional","affiliation":[{"name":"Department of Drug Safety Sciences, Division of Clinical Pharmacology, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Akai, S., Uematsu, Y., Tsuneyama, K., Oda, S. and Yokoi, T. (2016): Kupffer cell-mediated exacerbation of methimazole-induced acute liver injury in rats. J. Appl. Toxicol., <b>36<\/b>, 702-715.","DOI":"10.1002\/jat.3202"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bhushan, B. and Apte, U. (2019): Liver regeneration after acetaminophen hepatotoxicity: mechanisms and therapeutic opportunities. Am. J. Pathol., <b>189<\/b>, 719-729.","DOI":"10.1016\/j.ajpath.2018.12.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bird, T.G., M\u00fcller, M., Boulter, L., Vincent, D.F., Ridgway, R.A., Lopez-Guadamillas, E., Lu, W.Y., Jamieson, T., Govaere, O., Campbell, A.D., Ferreira-Gonzalez, S., Cole, A.M., Hay, T., Simpson, K.J., Clark, W., Hedley, A., Clarke, M., Gentaz, P., Nixon, C., Bryce, S., Kiourtis, C., Sprangers, J., Nibbs, R.J., Van Rooijen, N., Bartholin, L., McGreal, S.R., Apte, U., Barry, S.T., Iredale, J.P., Clarke, A.R., Serrano, M., Roskams, T.A., Sansom, O.J. and Forbes, S.J. (2018): TGF\u03b2 inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence. Sci. Transl. Med., <b>10<\/b>, eaan1230.","DOI":"10.1126\/scitranslmed.aan1230"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Cataldo, V.D., Gibbons, D.L., P\u00e9rez-Soler, R. and Quint\u00e1s-Cardama, A. (2011): Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med., <b>364<\/b>, 947-955.","DOI":"10.1056\/NEJMct0807960"},{"key":"5","first-page":"1","year":"2018","unstructured":"Chen, R., Wang, B., Liu, Y., Lin, R., He, J. and Li, D. (2018): A study of cryogenic tissue-engineered liver slices in calcium alginate gel for drug testing. Cryobiology, <b>82<\/b>, 1-7.","journal-title":"Cryobiology","ISSN":"http:\/\/id.crossref.org\/issn\/0011-2240","issn-type":"print"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Circu, M.L. and Aw, T.Y. (2010): Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med., <b>48<\/b>, 749-762.","DOI":"10.1016\/j.freeradbiomed.2009.12.022"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Ding, P.N., Lord, S.J., Gebski, V., Links, M., Bray, V., Gralla, R.J., Yang, J.C. and Lee, C.K. (2017): Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: A meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced <i>EGFR<\/i>-mutated non-small cell lung cancer. J. Thorac. Oncol., <b>12<\/b>, 633-643.","DOI":"10.1016\/j.jtho.2016.11.2236"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Dutto, I., Tillhon, M., Cazzalini, O., Stivala, L.A. and Prosperi, E. (2015): Biology of the cell cycle inhibitor p21(CDKN1A): molecular mechanisms and relevance in chemical toxicology. Arch. Toxicol., <b>89<\/b>, 155-178.","DOI":"10.1007\/s00204-014-1430-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Elsherbiny, M.E. and Brocks, D.R. (2011): The ability of polycyclic aromatic hydrocarbons to alter physiological factors underlying drug disposition. Drug Metab. Rev., <b>43<\/b>, 457-475.","DOI":"10.3109\/03602532.2011.596204"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Forman, H.J., Zhang, H. and Rinna, A. (2009): Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol. Aspects Med., <b>30<\/b>, 1-12.","DOI":"10.1016\/j.mam.2008.08.006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Griffith, O.W. (1982): Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J. Biol. Chem., <b>257<\/b>, 13704-13712.","DOI":"10.1016\/S0021-9258(18)33504-X"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Harmsen, S., Meijerman, I., Beijnen, J.H. and Schellens, J.H. (2009): Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother. Pharmacol., <b>64<\/b>, 35-43.","DOI":"10.1007\/s00280-008-0842-3"},{"key":"13","unstructured":"Ho, C., Davis, J., Anderson, F., Bebb, G. and Murray, N. (2005): Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J. Clin. Oncol., <b>23<\/b>, 8531-8533."},{"key":"14","doi-asserted-by":"crossref","unstructured":"James, L.P., Mayeux, P.R. and Hinson, J.A. (2003): Acetaminophen-induced hepatotoxicity. Drug Metab. Dispos., <b>31<\/b>, 1499-1506.","DOI":"10.1124\/dmd.31.12.1499"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Klaassen, C.D. and Reisman, S.A. (2010): Nrf2 the rescue: effects of the antioxidative\/electrophilic response on the liver. Toxicol. Appl. Pharmacol., <b>244<\/b>, 57-65.","DOI":"10.1016\/j.taap.2010.01.013"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Kobayashi, M., Higuchi, S., Ide, M., Nishikawa, S., Fukami, T., Nakajima, M. and Yokoi, T. (2012): Th2 cytokine-mediated methimazole-induced acute liver injury in mice. J. Appl. Toxicol., <b>32<\/b>, 823-833.","DOI":"10.1002\/jat.2731"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Lee, C.K., Brown, C., Gralla, R.J., Hirsh, V., Thongprasert, S., Tsai, C.M., Tan, E.H., Ho, J.C., Chu, T., Zaatar, A., Osorio Sanchez, J.A., Vu, V.V., Au, J.S., Inoue, A., Lee, S.M., Gebski, V. and Yang, J.C. (2013): Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J. Natl. Cancer Inst., <b>105<\/b>, 595-605.","DOI":"10.1093\/jnci\/djt072"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Li, J., Zhao, M., He, P., Hidalgo, M. and Baker, S.D. (2007): Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res., <b>13<\/b>, 3731-3737.","DOI":"10.1158\/1078-0432.CCR-07-0088"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Li, X., Kamenecka, T.M. and Cameron, M.D. (2009): Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem. Res. Toxicol., <b>22<\/b>, 1736-1742.","DOI":"10.1021\/tx900256y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Liu, X., Lu, Y., Guan, X., Dong, B., Chavan, H., Wang, J., Zhang, Y., Krishnamurthy, P. and Li, F. (2015): Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism. Biochem. Pharmacol., <b>97<\/b>, 111-121.","DOI":"10.1016\/j.bcp.2015.07.010"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J. and Haber, D.A. (2004): Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., <b>350<\/b>, 2129-2139.","DOI":"10.1056\/NEJMoa040938"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S. and Nukiwa, T.; North-East Japan Study Group. (2010): Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med., <b>362<\/b>, 2380-2388.","DOI":"10.1056\/NEJMoa0909530"},{"key":"23","first-page":"54","year":"2011","unstructured":"Masubuchi, Y., Nakayama, J. and Watanabe, Y. (2011): Sex difference in susceptibility to acetaminophen hepatotoxicity is reversed by buthionine sulfoximine. Toxicology, <b>287<\/b>, 54-60.","journal-title":"Toxicology","ISSN":"http:\/\/id.crossref.org\/issn\/0300-483X","issn-type":"print"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Masuyama, H., Suwaki, N., Tateishi, Y., Nakatsukasa, H., Segawa, T. and Hiramatsu, Y. (2005): The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol. Endocrinol., <b>19<\/b>, 1170-1180.","DOI":"10.1210\/me.2004-0434"},{"key":"25","doi-asserted-by":"publisher","unstructured":"McKillop, D., Hutchison, M., Partridge, E.A., Bushby, N., Cooper, C.M., Clarkson-Jones, J.A., Herron, W. and Swaisland, H.C. (2004a): Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica, <b>34<\/b>, 917-934.","DOI":"10.1080\/00498250400009171"},{"key":"26","doi-asserted-by":"crossref","unstructured":"McKillop, D., McCormick, A.D., Miles, G.S., Phillips, P.J., Pickup, K.J., Bushby, N. and Hutchison, M. (2004b): <i>In vitro<\/i> metabolism of gefitinib in human liver microsomes. Xenobiotica, <b>34<\/b>, 983-1000.","DOI":"10.1080\/02772240400015222"},{"key":"27","doi-asserted-by":"crossref","unstructured":"McKillop, D., McCormick, A.D., Millar, A., Miles, G.S., Phillips, P.J. and Hutchison, M. (2005): Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica, <b>35<\/b>, 39-50.","DOI":"10.1080\/00498250400026464"},{"key":"28","doi-asserted-by":"crossref","unstructured":"McKillop, D., Partridge, E.A., Hutchison, M., Rhead, S.A., Parry, A.C., Bardsley, J., Woodman, H.M. and Swaisland, H.C. (2004c): Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica, <b>34<\/b>, 901-915.","DOI":"10.1080\/00498250400009189"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K. and Fukuoka, M.; West Japan Oncology Group. (2010): Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol., <b>11<\/b>, 121-128.","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Natarajan, A., Wagner, B. and Sibilia, M. (2007): The EGF receptor is required for efficient liver regeneration. Proc. Natl. Acad. Sci. USA, <b>104<\/b>, 17081-17086.","DOI":"10.1073\/pnas.0704126104"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Satoh, T.K., Mellett, M., Meier-Schiesser, B., Fenini, G., Otsuka, A., Beer, H.D., Rordorf, T., Maul, J.T., Hafner, J., Navarini, A.A., Contassot, E. and French, L.E. (2020): IL-36\u03b3 drives skin toxicity induced by EGFR\/MEK inhibition and commensal <i>Cutibacterium acnes.<\/i> J. Clin. Invest., <b>130<\/b>, 1417-1430.","DOI":"10.1172\/JCI128678"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Shimizu, S., Atsumi, R., Itokawa, K., Iwasaki, M., Aoki, T., Ono, C., Izumi, T., Sudo, K. and Okazaki, O. (2009): Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice. Arch. Toxicol., <b>83<\/b>, 701-707.","DOI":"10.1007\/s00204-009-0436-9"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Shimizu, S., Atsumi, R., Nakazawa, T., Izumi, T., Sudo, K., Okazaki, O. and Saji, H. (2011): Ticlopidine-induced hepatotoxicity in a GSH-depleted rat model. Arch. Toxicol., <b>85<\/b>, 347-353.","DOI":"10.1007\/s00204-010-0594-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Stepan, A.F., Walker, D.P., Bauman, J., Price, D.A., Baillie, T.A., Kalgutkar, A.S. and Aleo, M.D. (2011): Structural alert\/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol., <b>24<\/b>, 1345-1410.","DOI":"10.1021\/tx200168d"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Sugiura, Y., Nemoto, E., Kawai, O., Ohkubo, Y., Fusegawa, H. and Kaseda, S. (2013): Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy. Lung Cancer (Auckl.), <b>4<\/b>, 9-14.","DOI":"10.2147\/LCTT.S45172"},{"key":"36","first-page":"74","year":"2015","unstructured":"Takeda, M., Okamoto, I. and Nakagawa, K. (2015): Pooled safety analysis of EGFR-TKI treatment for <i>EGFR<\/i> mutation-positive non-small cell lung cancer. Lung Cancer, <b>88<\/b>, 74-79.","journal-title":"Lung Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Wang, D.D., Liu, Y., Li, N., Zhang, Y., Jin, Q., Hao, D.C., Piao, H.L., Dai, Z.R., Ge, G.B. and Yang, L. (2017): Induction of CYP1A1 increases gefitinib-induced oxidative stress and apoptosis in A549 cells. Toxicol. In Vitro, <b>44<\/b>, 36-43.","DOI":"10.1016\/j.tiv.2017.06.022"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Watanabe, T., Sagisaka, H., Arakawa, S., Shibaya, Y., Watanabe, M., Igarashi, I., Tanaka, K., Totsuka, S., Takasaki, W. and Manabe, S. (2003): A novel model of continuous depletion of glutathione in mice treated with L-buthionine (S,R)-sulfoximine. J. Toxicol. Sci., <b>28<\/b>, 455-469.","DOI":"10.2131\/jts.28.455"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Xu, J., Oda, S. and Yokoi, T. (2018): Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. Toxicol. In Vitro, <b>48<\/b>, 286-301.","DOI":"10.1016\/j.tiv.2018.01.019"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Yang, Z., Hackshaw, A., Feng, Q., Fu, X., Zhang, Y., Mao, C. and Tang, J. (2017): Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int. J. Cancer, <b>140<\/b>, 2805-2819.","DOI":"10.1002\/ijc.30691"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Yoshinari, K., Ueda, R., Kusano, K., Yoshimura, T., Nagata, K. and Yamazoe, Y. (2008): Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem. Pharmacol., <b>76<\/b>, 139-145.","DOI":"10.1016\/j.bcp.2008.04.005"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/45\/8\/45_493\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T14:36:25Z","timestamp":1616855785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/45\/8\/45_493\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.45.493","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}